New Drug Authorised by the FDA in USA for Clear Cell Sarcoma

At the end of October 2020 the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for CPI-613® (devimistat) for the treatment of soft tissue sarcoma.

This is a potentially very exciting first step for a drug which may help Clear Cell Sarcoma patients who up to now have had no effective available treatments.

Devimistat targets enzymes that are involved in tumor cell multiplication and substantially increases the sensitivity of cancer cells to a diverse range of chemotherapeutic agents. This allows for potential combinations of devimistat with lower doses of generally toxic chemotherapy drugs to be more effective with lower patient’s side effects.

This is very promising start and hopefully the clinical evidence will back up the hope the devimistat is offering to patients.